ADPN is emerging as an interesting molecule with potential implications as a therapeutic target and a biomarker in metabolic and inflammatory diseases, including eating disorders, IBD/IBS, and obesity. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.